-
Views
-
Cite
Cite
D. Bouazzi, M.L. McPhie, R. Kjærsgaard Andersen, A. Alavi, G.B.E. Jemec, Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study, British Journal of Dermatology, Volume 184, Issue 3, 1 March 2021, Pages 570–571, https://doi.org/10.1111/bjd.19626
- Share Icon Share
Extract
The Department of Dermatology, Zealand University Hospital is a part of the European Reference Network for skin diseases.
Funding sources: none.
Conflicts of interest: D.B., M.L.M. and R.K.A. declare they have no conflicts of interest. G.B.E.J. has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, InflaRx, Novartis, Pierre Fabre and UCB for participation on advisory boards; has received grants from AbbVie, AstraZeneca, InflaRx, Janssen‐Cilag, LEO Pharma, Novartis, Regeneron, Sanofi and UCB for participation as an investigator; has received speaker honoraria from AbbVie, Boehringer Ingelheim and Galderma; and has received unrestricted departmental grants from AbbVie, LEO Pharma and Novartis. A.A. has received honoraria as a consultant, speaker or advisory board participant from AbbVie, Galderma, Janssen, LEO, Novartis, Sanofi and Valeant; has received grants from AbbVie, Boehringer Ingelheim and Kymera; and has been a research investigator for AbbVie, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Genentech, Glenmark, Incyte, InflaRx, Janssen, Kymera, Kyowa, LEO, Novartis, Pfizer, Regeneron and UCB.